Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | DDX3X | O00571 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488133 | 0.91 | CNR1 (0.64) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6489054 | 0.91 | CNR1 (0.57) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6478776 | 0.90 | MEN1 (0.65) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6490705 | 0.90 | TRPV1 (0.58) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6480620 | 0.89 | MGLL (0.51) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6480400 | 0.88 | MGLL (0.50) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6490081 | 0.88 | TRPV1 (0.60) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6487078 | 0.88 | TRPV1 (0.54) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6479242 | 0.87 | DDX3X (0.51) | MGLLTRPV1CNR1MEN1KMT2A | |
| SCHEMBL6479088 | 0.86 | CNR1 (0.60) | MGLLTRPV1CNR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1461311-A2 | UREA DERIVATIVES AS VR1-ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055848-A2 | UREA DERIVATIVES AS VR1- ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | SLC14A1, UBA1, VAT1 | MGLL 4556/4885TRPV1 214/4885CNR1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.